# Peter van Schijndel

Peter maakt deel uit van het team dat HOYNG ROKH MONEGIER in 2011 heeft opgericht en werd in 2017 benoemd tot partner. Hij is gespecialiseerd in octrooirecht, met een bijzondere focus op de farmaceutische, biotechnologische en medical devices industrie De meeste zaken van Peter hebben een internationale dimensie en hij heeft uitgebreide ervaring in het coördineren van intellectuele-eigendomsgeschillen in meerdere rechtsgebieden.

Cliënten in de farmaceutische en biotechnologische sector zijn onder meer AbbVie, Abbott, Biogen, Johnson & Johnson, Gilead, Sanofi, Pfizer, UCB en Regeneron.



### Representatieve zaken

- Centocor (Johnson & Johnson) v Bayer, concerning the anti-TNF-alpha drug golimumab.
- Abbott v Medinol, concerning coronary stents.
- Medimmune v Novartis, concerning the basic patents on phage display.
- AGA v Occlutech, concerning cardiac implants (ASD/PFO occluders).
- RCT v Accord, concerning lacosamide.
- Warner Lambert v Dutch State, concerning pregabalin and regulatory law (ECJ referral).
- Royalty Pharma v MSD, concerning DPP-4 inhibitors.
- AbbVie v Biosimilars, concerning the defense of AbbVie’s portfolio of patents on adalimumab (Humira).
- Abbott v Edwards, concerning heart implants.
- Regeneron v Amgen, concerning PCSK9 inhibitors.
- Wyeth v MSD, concerning multivalent pneumococcal vaccines.
- CEVA v Bayer, concerning a veterinary combination drug against anaemia and coccidiosis.
- Apple v Ericsson, on 4G/5G telecom technology
- BioNtech / Moderna, on MRNA vaccines
- Janssen / Samsung, on an IL12/IL23 antibody for the treatment of ulcerative colitis
- Regeneron / Samsung, concerning VEGF-antagonists for wAMD
- Gilead / AMMS (UPC), concerning SARS-CoV-2 therapies
- Washtower / BEGA (UPC), concerning a mechanical invention and the doctrine of equivalence.





### Professionele lidmaatschappen

- AIPPI
- Bestuurslid VIEPA





### Lezingen

- Regelmatig spreker over onderwerpen met betrekking tot octrooigeschillen





### Wat anderen zeggen

- “Peter van Schijndel has a deep understanding of both complex patent issues and the pharmaceutical industry. His written court submissions are persuasive and well reasoned. He also thinks creatively and collaborates well with teams around the world.”
    “Peter always does an excellent job, remaining well argued, concise and a quick thinker who fights for his views.” **IAM Patent 2025**
- “Successful patent litigator.” **IAM Patent 2024**
- “Peter excels in patent matters and also works at the forefront of cutting-edge issues” IAM Patent 2023
- “Peter van Schijndel has a very strong professional experience.” Legal 500 2023
- Great technical background; does a very good job.” JUVE Patent 2022
- “Peter is really knowledgeable about the law and thinks strategically.” IAM Patent 2022
- “Very experienced in pharma patent litigation. Pragmatic and creative when considering legal issues, and responsive.” **Legal 500 2022**
- “Impressive in building up his own name, with a strong client base” and “cuts an impressive figure in his cases” JUVE Patent 2021
- “Biotech superstar” IAM Patent 1000 2021
- “A very good life sciences litigator” WWL 2021
- “Calculated and fast-thinking practitioner whom top companies are eager to have on side.” **IAM Patent 1000 2020**
- “He impressed.” **Legal 500 2020**
- “Very visible in pharma cases.” **JUVE Patent 2020**
- “Peter van Schijndel is ‘a very strong litigator with a keen focus on pharmaceuticals’. He is a ‘smart innovative thinker’ and ‘always a step ahead of the other side’ thanks to his ‘sharp and skilled approach’” WWL Lifesciences 2019









### Representatieve zaken



- Centocor (Johnson & Johnson) v Bayer, concerning the anti-TNF-alpha drug golimumab.
- Abbott v Medinol, concerning coronary stents.
- Medimmune v Novartis, concerning the basic patents on phage display.
- AGA v Occlutech, concerning cardiac implants (ASD/PFO occluders).
- RCT v Accord, concerning lacosamide.
- Warner Lambert v Dutch State, concerning pregabalin and regulatory law (ECJ referral).
- Royalty Pharma v MSD, concerning DPP-4 inhibitors.
- AbbVie v Biosimilars, concerning the defense of AbbVie’s portfolio of patents on adalimumab (Humira).
- Abbott v Edwards, concerning heart implants.
- Regeneron v Amgen, concerning PCSK9 inhibitors.
- Wyeth v MSD, concerning multivalent pneumococcal vaccines.
- CEVA v Bayer, concerning a veterinary combination drug against anaemia and coccidiosis.
- Apple v Ericsson, on 4G/5G telecom technology
- BioNtech / Moderna, on MRNA vaccines
- Janssen / Samsung, on an IL12/IL23 antibody for the treatment of ulcerative colitis
- Regeneron / Samsung, concerning VEGF-antagonists for wAMD
- Gilead / AMMS (UPC), concerning SARS-CoV-2 therapies
- Washtower / BEGA (UPC), concerning a mechanical invention and the doctrine of equivalence.



## Professionele lidmaatschappen



- AIPPI
- Bestuurslid VIEPA



## Lezingen



- Regelmatig spreker over onderwerpen met betrekking tot octrooigeschillen



## Wat anderen zeggen



- “Peter van Schijndel has a deep understanding of both complex patent issues and the pharmaceutical industry. His written court submissions are persuasive and well reasoned. He also thinks creatively and collaborates well with teams around the world.”
    “Peter always does an excellent job, remaining well argued, concise and a quick thinker who fights for his views.” **IAM Patent 2025**
- “Successful patent litigator.” **IAM Patent 2024**
- “Peter excels in patent matters and also works at the forefront of cutting-edge issues” IAM Patent 2023
- “Peter van Schijndel has a very strong professional experience.” Legal 500 2023
- Great technical background; does a very good job.” JUVE Patent 2022
- “Peter is really knowledgeable about the law and thinks strategically.” IAM Patent 2022
- “Very experienced in pharma patent litigation. Pragmatic and creative when considering legal issues, and responsive.” **Legal 500 2022**
- “Impressive in building up his own name, with a strong client base” and “cuts an impressive figure in his cases” JUVE Patent 2021
- “Biotech superstar” IAM Patent 1000 2021
- “A very good life sciences litigator” WWL 2021
- “Calculated and fast-thinking practitioner whom top companies are eager to have on side.” **IAM Patent 1000 2020**
- “He impressed.” **Legal 500 2020**
- “Very visible in pharma cases.” **JUVE Patent 2020**
- “Peter van Schijndel is ‘a very strong litigator with a keen focus on pharmaceuticals’. He is a ‘smart innovative thinker’ and ‘always a step ahead of the other side’ thanks to his ‘sharp and skilled approach’” WWL Lifesciences 2019